Literature DB >> 23152734

Fecal microbiota transplantation in relapsing Clostridium difficile infection.

Faith Rohlke1, Neil Stollman.   

Abstract

Clostridium difficile infection rates are Climbing in frequency and severity, and the spectrum of susceptible patients is expanding beyond the traditional scope of hospitalized patients receiving antibiotics. Fecal microbiota transplantation is becoming increasingly accepted as an effective and safe intervention in patients with recurrent disease, likely due to the restoration of a disrupted microbiome. Cure rates of > 90% are being consistently reported from multiple centers. Transplantation can be provided through a variety of methodologies, either to the lower proximal, lower distal, or upper gastrointestinal tract. This review summarizes reported results, factors in donor selection, appropriate patient criteria, and the various preparations and mechanisms of fecal microbiota transplant delivery available to clinicians and patients.

Entities:  

Keywords:  Clostridium difficile; fecal bacteriotherapy; fecal flora; fecal flora reconstitution; fecal microbiota transplantation; fecal transplant; recurrent Clostridium difficile infection; stool transplantation

Year:  2012        PMID: 23152734      PMCID: PMC3491681          DOI: 10.1177/1756283X12453637

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  77 in total

1.  Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope.

Authors:  S E Persky; L J Brandt
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

2.  "Flora Power"-- fecal bacteria cure chronic C. difficile diarrhea.

Authors:  T J Borody
Journal:  Am J Gastroenterol       Date:  2000-11       Impact factor: 10.864

Review 3.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

4.  Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis.

Authors:  B EISEMAN; W SILEN; G S BASCOM; A J KAUVAR
Journal:  Surgery       Date:  1958-11       Impact factor: 3.982

5.  The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea.

Authors:  A Gustafsson; A Berstad; S Lund-Tønnesen; T Midtvedt; E Norin
Journal:  Scand J Gastroenterol       Date:  1999-06       Impact factor: 2.423

6.  Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.

Authors:  Lorraine Kyne; Stavros Sougioultzis; Lynne V McFarland; Ciarán P Kelly
Journal:  Infect Control Hosp Epidemiol       Date:  2002-11       Impact factor: 3.254

7.  Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube.

Authors:  Johannes Aas; Charles E Gessert; Johan S Bakken
Journal:  Clin Infect Dis       Date:  2003-02-14       Impact factor: 9.079

8.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.

Authors:  Lynne V McFarland; Gary W Elmer; Christina M Surawicz
Journal:  Am J Gastroenterol       Date:  2002-07       Impact factor: 10.864

Review 9.  Bacteriotherapy using fecal flora: toying with human motions.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn M Leis; Rosa Surace; Ori Ashman; Steven Siarakas
Journal:  J Clin Gastroenterol       Date:  2004-07       Impact factor: 3.062

10.  Treatment of ulcerative colitis using fecal bacteriotherapy.

Authors:  Thomas J Borody; Eloise F Warren; Sharyn Leis; Rosa Surace; Ori Ashman
Journal:  J Clin Gastroenterol       Date:  2003-07       Impact factor: 3.062

View more
  59 in total

Review 1.  Technical Aspects of Fecal Microbial Transplantation (FMT).

Authors:  N Bhutiani; J E Schucht; K R Miller; Stephen A McClave
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 2.  A day in the life of the meta-organism: diurnal rhythms of the intestinal microbiome and its host.

Authors:  Christoph A Thaiss; David Zeevi; Maayan Levy; Eran Segal; Eran Elinav
Journal:  Gut Microbes       Date:  2015

Review 3.  Microbiome diurnal rhythmicity and its impact on host physiology and disease risk.

Authors:  Samuel Philip Nobs; Timur Tuganbaev; Eran Elinav
Journal:  EMBO Rep       Date:  2019-03-15       Impact factor: 8.807

Review 4.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

5.  MIG1 Regulates Resistance of Candida albicans against the Fungistatic Effect of Weak Organic Acids.

Authors:  Fabien Cottier; Alrina Shin Min Tan; Xiaoli Xu; Yue Wang; Norman Pavelka
Journal:  Eukaryot Cell       Date:  2015-08-21

6.  Something old, something new, something borrowed...

Authors:  Louis Valiquette; Kevin B Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

Review 7.  What goes around comes around: novel pharmacological targets in the gut-brain axis.

Authors:  Camila González-Arancibia; Jorge Escobar-Luna; Camila Barrera-Bugueño; Camilo Díaz-Zepeda; María P González-Toro; Loreto Olavarría-Ramírez; Francesca Zanelli-Massai; Martin Gotteland; Javier A Bravo; Marcela Julio-Pieper
Journal:  Therap Adv Gastroenterol       Date:  2016-02-17       Impact factor: 4.409

Review 8.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

Review 9.  The importance of the microbiome in pediatrics and pediatric infectious diseases.

Authors:  Thaidra Gaufin; Nicole H Tobin; Grace M Aldrovandi
Journal:  Curr Opin Pediatr       Date:  2018-02       Impact factor: 2.856

Review 10.  Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis.

Authors:  Kelcie Witges; Leigh Anne Shafer; Ryan Zarychanski; Ahmed M Abou-Setta; Rasheda Rabbani; Orvie Dingwall; Charles N Bernstein
Journal:  Drug Saf       Date:  2020-12       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.